A third generation taxane classified as a New Chemical Entity (NCE)
Route of Administration
Mode of Action
Phase 2 studies in taxane-refractory solid tumors have indicated a substantial level of antitumor activity
The top (4) taxanes sold over $3 Billion worldwide in 2006.